--- title: "From Strategy to First-in-Human: A Practical Roadmap for Biotech Development" description: "Early-stage biotech teams often struggle to translate scientific innovation into first-in-human readiness. This webinar provides practical guidance to help teams build a clear, scalable development pathway that aligns regulatory strategy, CMC, quality, and clinical planning. Reducing risk, avoiding delays, and staying inspection-ready without overbuilding internal structures." url: https://qbdgroup.com/en/webinars/from-strategy-to-first-in-human type: "Webinar" language: en published: 2026-03-18 author: "QbD Group" category: "Pharma & Biotech" publisher: "QbD Group" citation: "QbD Group, \"From Strategy to First-in-Human: A Practical Roadmap for Biotech Development\", https://qbdgroup.com/en/webinars/from-strategy-to-first-in-human" --- # From Strategy to First-in-Human: A Practical Roadmap for Biotech Development > Early-stage biotech teams often struggle to translate scientific innovation into first-in-human readiness. This webinar provides practical guidance to help teams build a clear, scalable development pathway that aligns regulatory strategy, CMC, quality, and clinical planning. Reducing risk, avoiding delays, and staying inspection-ready without overbuilding internal structures. Early-stage biotech teams often struggle to translate scientific innovation into first-in-human readiness. This webinar provides practical guidance to help teams build a clear, scalable development pathway that aligns regulatory strategy, CMC, quality, and clinical planning. Reducing risk, avoiding delays, and staying inspection-ready without overbuilding internal structures. [Learn more](https://qbdgroup.com/en/webinars/from-strategy-to-first-in-human#register-here) March 18, 2026 16:00-17:00 CET Pharma & Biotech English #### Build a scalable path from strategy to first-in-human Biotech startups and early-stage companies face a critical transition when moving from scientific innovation to first-in-human clinical trials. At this stage, **early strategic decisions often determine whether development progresses smoothly or becomes slowed** by regulatory questions, CTA delays, and costly rework. Fragmented regulatory planning, limited internal quality and pharmacovigilance infrastructure, and misalignment between development stages are common challenges across early biotech programs. These gaps frequently remain hidden until late in development, when timelines and budgets are already under pressure. Based on real-world regulatory interactions and development experience, **this webinar explores the full journey from early strategic planning to first-in-human readiness** highlighting how regulatory strategy, scientific advice, CMC and GMP preparedness, and early clinical and safety oversight must work together as a coherent pathway. Rather than focusing on individual services, **the session provides a practical roadmap to help biotech teams make better early decisions, align critical activities, and progress toward first-in-human studies** with greater confidence and control. #### What you'll learn - How **early strategic choices** affect CTA readiness, regulatory interactions, and first-in-human timelines. - Common **gaps** that cause **delays and rework**, and how to spot them early. - How to **align regulatory strategy, CMC, quality systems, and safety oversight** across development stages. - What **practical readiness** looks like and how to **build scalable foundations** without unnecessary complexity. - Why an **end-to-end, integrated approach** reduces regulatory risk and speeds predictable execution. ## Register here First name\* Last name\* Role\* Department\* Professional Email\* Company name\* Industry \* Country\* Would you like a one-on-one with our team?\* Content Industry -  Yes, I agree to receive personalized newsletters with market insights, invitations for exclusive events and educational webinars from the QbD Group. \* ## Who should attend? This webinar is ideal for decision-makers and technical leaders shaping early-stage biotech development, including: - **Founders, CEOs, and COOs of biotech startups** who are guiding early development strategy and preparing their organizations for first-in-human milestones. - **Regulatory Affairs Directors and Managers** responsible for defining regulatory pathways, managing CTA readiness, and engaging with health authorities. - **Heads of CMC and Technical Operations** overseeing process development, manufacturing strategy, and GMP preparedness for early clinical supply. - **Clinical Development and Clinical Operations leaders** planning first-in-human studies, trial execution, and cross-functional alignment. - **QA and GxP Compliance leads in early clinical development** responsible for building scalable quality systems and inspection-ready frameworks. [Learn from our experts](https://qbdgroup.com/en/webinars/from-strategy-to-first-in-human#register-here) ## Speakers Our speakers combine deep expertise in early-stage biotech development, regulatory affairs, and clinical readiness. They will share practical insights to help teams align strategy, reduce risk, and accelerate progress toward first-in-human trials. #### Angeles Escarti-Nebot, PhD Global Head Regulatory Affairs Ángeles is Global Head of Regulatory Affairs at QbD Group, with over 17 years of experience in biotechnology and pharmaceutical development. She has extensive expertise in regulatory strategy, compliance, and interactions with FDA, EMA, MHRA, and other national authorities. Throughout her career, Ángeles has advised companies on regulatory pathways, risk assessment, and expedited product development, building high-performing teams and achieving key regulatory milestones to accelerate development and ensure market success. She is also passionate about the potential of data and AI to transform regulatory strategy in the life sciences sector. ![Sacha Lynch](https://jrtdedcfhvzaomneervp.supabase.co/storage/v1/object/public/avatars/sacha-lynch.png) #### Sacha Lynch Director Regulatory Affairs UK Sacha has over 20 years of experience in European Regulatory Affairs with expertise spanning product development to post approval. Her educational background includes a degree in pharmacology and medical sciences, complemented by a master’s in clinical research. Sacha’s career has predominantly  focused in supporting companies in developing clinical strategies and driving regulatory activities engaging with regulatory agencies through scientific advice leading MAA submissions. Currently she is a Principal consultant with QbD Group, where she continues to support clients and leads project teams to develop robust strategies in their clinical development. Sacha actively contributes to the profession and leads the introductory course for TOPRA [Reserve your spot](https://qbdgroup.com/en/webinars/from-strategy-to-first-in-human#register-here) ## Resources you might find interesting ![preview_image](https://jrtdedcfhvzaomneervp.supabase.co/storage/v1/object/public/webinar-images/webinars/content/from-strategy-to-first-in-human/Scaling_PV_Governance_in_Europe_Maintaining_Oversight_as_Organizations_Grow.jpg) Blog #### Scaling PV Governance in Europe: Maintaining Oversight as Organizations Grow For many European SMEs and biotechs, pharmacovigilance typically begins as a... [Read More](https://qbdgroup.com/en/blog/scaling-pv-governance-europe-eu-qppv-oversight) ![preview_image](https://jrtdedcfhvzaomneervp.supabase.co/storage/v1/object/public/webinar-images/webinars/content/from-strategy-to-first-in-human/Cleanrooms__Isolators_and_RABS_Meeting_Annex_1_Expectations_for_Modern_Aseptic_Manufacturing.png) Blog #### Cleanrooms, Isolators and RABS: Meeting Annex 1 Expectations for Modern Aseptic Manufacturing EU GMP Annex 1 has accelerated a shift that many manufacturers were... [Read More](https://qbdgroup.com/en/blog/annex-1-cleanrooms-isolators-rabs-aseptic-manufacturing) ![preview_image](https://jrtdedcfhvzaomneervp.supabase.co/storage/v1/object/public/webinar-images/webinars/content/from-strategy-to-first-in-human/Early_Orphan_Strategy_Regulatory_and_Commercial_Considerations_Across_EU__US_and_UK.png) Blog #### Deciding Early on an Orphan Strategy: A Strategic Choice, Not a Checkbox Deciding whether an orphan strategy fits a development program... [Read More](https://qbdgroup.com/en/blog/early-orphan-strategy-eu-us-uk) ![preview_image](https://jrtdedcfhvzaomneervp.supabase.co/storage/v1/object/public/webinar-images/webinars/content/from-strategy-to-first-in-human/Diseno-sin-titulo-1-4-2.jpg) Blog #### Nitrosamine Impurities in Medicinal Products: Risks and Regulatory Insights The emergence of nitrosamine impurities In June 2018, regulatory... [Read More](https://qbdgroup.com/en/blog/nitrosamine-impurities-in-medicinal-products-risks-and-regulatory-insights) ![preview_image](https://jrtdedcfhvzaomneervp.supabase.co/storage/v1/object/public/webinar-images/webinars/content/from-strategy-to-first-in-human/Strategic_Choices_That_Define_a_Biotech_s_Path_to_the_Clinic_First-in-Human_Is_Earned_Long_Before_It_Begins.jpg) Blog #### Strategic Choices That Define a Biotech’s Path to the Clinic: First-in-Human Is Earned Long Before It Begins For early-stage biotech teams, the most consequential decisions are... [Read More](https://qbdgroup.com/en/blog/early-biotech-strategy-first-in-human-eu-uk) ![preview_image](https://jrtdedcfhvzaomneervp.supabase.co/storage/v1/object/public/webinar-images/webinars/content/from-strategy-to-first-in-human/New_Update_of_Appendix_1_of_the_Nitrosamines_Guideline_2_-_RA_Update.jpg) Blog #### New Update of Appendix 1 of the Nitrosamines Guideline - EMA/42261/2025/Rev. 11 What's new? This update introduces the Acceptable Intake (AI) values for new... ![preview_image](https://jrtdedcfhvzaomneervp.supabase.co/storage/v1/object/public/webinar-images/webinars/content/from-strategy-to-first-in-human/EU_New_Variations_Guidelines_to_Streamline_Lifecycle_Management_of_Medicines_-_QbD_Group.jpg) Blog #### EU New Variations Guidelines to Streamline Lifecycle Management of Medicines The aim of the newvariations framework is to streamline post-approval change... Blog #### EU Pharmacovigilance: Implementing Regulation (EU) 2025/1466 Key updates {% module\_block module... ![preview_image](https://jrtdedcfhvzaomneervp.supabase.co/storage/v1/object/public/webinar-images/webinars/content/from-strategy-to-first-in-human/RA_update_-_ICH_Draft_Q3E_Guideline_on_Extractables___Leachables_Now_Open_for_Consultation.jpg) Blog #### ICH Draft Q3E Guideline on Extractables & Leachables Now Open for Consultation This milestone represents a decisive step toward harmonizing international... Blog #### FDA Deadline Update - Risk of nitrosamine drug substance-related impurity (NDSRI) Key takeaways from the update: Confirmatory testing and risk evaluation must... --- Source: https://qbdgroup.com/en/webinars/from-strategy-to-first-in-human — © QbD Group. Quote freely with attribution and a link back.